C WorldWide Group Holding A S reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 17.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,452 shares of the biopharmaceutical company’s stock after selling 43,579 shares during the period. C WorldWide Group Holding A S’s holdings in Bristol-Myers Squibb were worth $13,080,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock worth $6,611,829,000 after purchasing an additional 333,685 shares during the last quarter. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 2.4% in the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock worth $5,541,612,000 after acquiring an additional 2,367,864 shares in the last quarter. Dodge & Cox grew its position in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock worth $1,648,168,000 after acquiring an additional 459,271 shares in the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% in the 3rd quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock worth $1,711,689,000 after acquiring an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after acquiring an additional 910,496 shares in the last quarter. 71.51% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE BMY opened at $60.88 on Friday. The stock has a market capitalization of $102,820.08, a price-to-earnings ratio of 20.23, a PEG ratio of 1.64 and a beta of 0.96. Bristol-Myers Squibb has a one year low of $51.56 and a one year high of $70.05. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.63 EPS. equities research analysts anticipate that Bristol-Myers Squibb will post 3.22 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Stockholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 2.63%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.
BMY has been the subject of several research reports. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price objective for the company. in a research report on Thursday, December 28th. Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $51.56 to $78.00 in a research report on Thursday, February 15th. BMO Capital Markets reiterated a “sell” rating and set a $52.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Finally, Leerink Swann boosted their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $66.68.
ILLEGAL ACTIVITY WARNING: “C WorldWide Group Holding A S Sells 43,579 Shares of Bristol-Myers Squibb (BMY)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/c-worldwide-group-holding-a-s-has-13-08-million-holdings-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.